PatientsVille.com Logo

Cubicin Side Effects

PatientsVille

Common Cubicin Side Effects


The most commonly reported Cubicin side effects (click to view or check a box to report):

Blood Creatine Phosphokinase Increased (192)
Eosinophilic Pneumonia (89)
Death (85)
Blood Creatinine Increased (73)
Renal Failure Acute (72)
Multi-organ Failure (68)
Rhabdomyolysis (66)
Pyrexia (65)
International Normalised Ratio Increased (58)
Septic Shock (56)
Eosinophilia (55)
Sepsis (51)
Endocarditis (50)
Renal Failure (49)
Myalgia (49)
Dyspnoea (49)
Aspartate Aminotransferase Increased (45)
Antimicrobial Susceptibility Test Resistant (44)
Alanine Aminotransferase Increased (40)
Rash (40)

➢ More



If you or someone in your family has experienced a serious side effect to a health product, you are encouraged to report the experience to your health care professional (e.g. physician, pharmacist). You could also complete a copy of the side effect reporting form or report your side effect to FDA.

Cubicin Side Effects Reported to FDA



Cubicin Side Effect Report#9921689
Hypoaesthesia, Paraesthesia, Neuralgia, Neuropathy Peripheral
This is a report of a 59-year-old female patient (weight: NA) from US, suffering from the following health symptoms/conditions: cellulitis, who was treated with Cubicin (daptomycin) (dosage: Q24hrs, start time:
Jan 16, 2014), combined with:
  • Vyvanse
  • Metformin
  • Singulair
  • Zolpidem
  • Venlafxine
and developed a serious reaction and side effect(s): Hypoaesthesia, Paraesthesia, Neuralgia, Neuropathy Peripheral after the beginning of treatment. This case can indicate the possible existence of increased vulnerability to Cubicin (daptomycin) treatment in female patients, resulting in Hypoaesthesia side effect.
Cubicin Side Effect Report#9906567
Eosinophilic Pneumonia, Abscess, Rash
This report suggests a potential Cubicin Eosinophilic Pneumonia side effect(s) that can have serious consequences. A female patient (weight: NA) from JP was diagnosed with the following symptoms/conditions: bacteraemia and used Cubicin (dosage: NA) starting
Jan 03, 2014. After starting Cubicin the patient began experiencing various side effects, including: Eosinophilic Pneumonia, Abscess, RashAdditional drugs used concurrently: NA. Although Cubicin demonstrated significant improvements in a number of clinically relevant cases, troublesome symptoms, such as Eosinophilic Pneumonia, may still occur.
Cubicin Side Effect Report#9902850
Circulatory Collapse, Septic Shock, Platelet Count Decreased, Bacteraemia, Pyrexia, Inflammation, Diffuse Cutaneous Mastocytosis, C-reactive Protein Increased, Confusional State
This Circulatory Collapse problem was reported by a health professional from FR. A 57-year-old male patient (weight: NA) was diagnosed with the following symptoms/conditions: NA. On 201312 this consumer started treatment with Cubicin (dosage: 420 Mg, Qd). The following drugs were being taken at the same time:
  • Ciclosporin (220 Mg, Qd)
  • Vancomycin (2.5 G, Qd)
  • Inexium//esomeprazole Magnesium (20 Mg, Qd)
  • Cefepime (2 G, Tid)
  • Tazocilline (1 Df, Qid (4g/500 Mg))
  • Heparin Sodium (7000 Iu, Qd)
  • Amikacide (1750 Mg, Qd)
  • Zelitrex (2 Df, Tid)
When using Cubicin, the patient experienced the following unwanted symptoms/side effects: Circulatory Collapse, Septic Shock, Platelet Count Decreased, Bacteraemia, Pyrexia, Inflammation, Diffuse Cutaneous Mastocytosis, C-reactive Protein Increased, Confusional StateThe patient was hospitalized.Although all drugs are carefully tested before they are licensed for use, they carry side effect risks. Some side effects, such as Circulatory Collapse, may become evident only after a product is in use by the general population.
Cubicin Side Effect Report#9893502
Lung Consolidation, Computerised Tomogram Abnormal
This Lung Consolidation side effect was reported by a consumer or non-health professional from US. A 29-year-old male patient (weight:NA) experienced the following symptoms/conditions: staphylococcal sepsis,pulmonary embolism,off label use.The patient was prescribed Cubicin (drug dosage: NA), which was initiated on NS. Concurrently used drugs: NA..After starting to take Cubicin the consumer reported adverse symptoms, such as: Lung Consolidation, Computerised Tomogram AbnormalThese side effects may potentially be related to Cubicin.
Cubicin Side Effect Report#9891969
This is a report of a 40-year-old male patient (weight: NA) from JP, suffering from the following health symptoms/conditions: sepsis, who was treated with Cubicin (dosage: 810 Mg, Qd, start time: 201401), combined with:
  • Meropen /01250501/ (0.5 G, Bid)
and developed a serious reaction and side effect(s): after the beginning of treatment. This case can indicate the possible existence of increased vulnerability to Cubicin treatment in male patients, resulting in Death side effect.
Cubicin Side Effect Report#9845210
Bone Marrow Failure
This report suggests a potential Cubicin Bone Marrow Failure side effect(s) that can have serious consequences. A 67-year-old male patient (weight: NA) from US was diagnosed with the following symptoms/conditions: staphylococcal infection,staphylococcal sepsis,fungal infection and used Cubicin (dosage: NA) starting
Nov 29, 2013. After starting Cubicin the patient began experiencing various side effects, including: Bone Marrow FailureAdditional drugs used concurrently:
  • Meropen
  • Funguard
  • Teicoplanin
  • Bfluid
  • Lasix
  • Miya Bm
  • Takepron
  • Mucodyne
Although Cubicin demonstrated significant improvements in a number of clinically relevant cases, troublesome symptoms, such as Bone Marrow Failure, may still occur.
Cubicin Side Effect Report#9782299
Systemic Inflammatory Response Syndrome, Osteomyelitis, Cellulitis, Rhabdomyolysis, Renal Failure, Blood Creatine Phosphokinase Increased
This Systemic Inflammatory Response Syndrome problem was reported by a consumer or non-health professional from US. A 53-year-old female patient (weight: NA) was diagnosed with the following symptoms/conditions: NA. On
Nov 12, 2013 this consumer started treatment with Cubicin (dosage: Unk). The following drugs were being taken at the same time:
  • Metformin Hydrochloride Sandoz (500 Mg, Bid)
  • Dapagliflozin (Unk)
  • Dapagliflozin (Unk)
  • Victoza (1.8 Mg, Qd)
  • Novolog (60 Iu, Tid)
  • Crestor (5 Mg, Qd)
  • Carvedilol
  • Metolazone
When using Cubicin, the patient experienced the following unwanted symptoms/side effects: Systemic Inflammatory Response Syndrome, Osteomyelitis, Cellulitis, Rhabdomyolysis, Renal Failure, Blood Creatine Phosphokinase IncreasedThe patient was hospitalized.Although all drugs are carefully tested before they are licensed for use, they carry side effect risks. Some side effects, such as Systemic Inflammatory Response Syndrome, may become evident only after a product is in use by the general population.
Cubicin Side Effect Report#9753703
Multi-organ Failure, Staphylococcal Sepsis
This Multi-organ Failure side effect was reported by a consumer or non-health professional from US. A 80-year-old female patient (weight:NA) experienced the following symptoms/conditions: staphylococcal infection,osteomyelitis,off label use.The patient was prescribed Cubicin (drug dosage: NA), which was initiated on NS. Concurrently used drugs: NA..After starting to take Cubicin the consumer reported adverse symptoms, such as: Multi-organ Failure, Staphylococcal SepsisThese side effects may potentially be related to Cubicin.
Cubicin Side Effect Report#9749906
Pyrexia, Cardiac Valve Replacement Complication, Mitral Valve Stenosis, Aortic Valve Incompetence
This is a report of a 54-year-old female patient (weight: NA) from US, suffering from the following health symptoms/conditions: endocarditis,bacteraemia,off label use, who was treated with Cubicin (dosage: Unk Unk, Unk, start time: NS), combined with: NA. and developed a serious reaction and side effect(s): Pyrexia, Cardiac Valve Replacement Complication, Mitral Valve Stenosis, Aortic Valve Incompetence after the beginning of treatment. This case can indicate the possible existence of increased vulnerability to Cubicin treatment in female patients, resulting in Pyrexia side effect. The patient was hospitalized.
Cubicin Side Effect Report#9745960
Pyrexia, Dyspnoea, Cough, Tachycardia, Pleuritic Pain, Pneumonitis
This report suggests a potential Cubicin Pyrexia side effect(s) that can have serious consequences. A 43-year-old male patient (weight: NA) from US was diagnosed with the following symptoms/conditions: staphylococcal infection and used Cubicin (dosage: NA) starting
Nov 11, 2013. After starting Cubicin the patient began experiencing various side effects, including: Pyrexia, Dyspnoea, Cough, Tachycardia, Pleuritic Pain, PneumonitisAdditional drugs used concurrently: NA.The patient was hospitalized. Although Cubicin demonstrated significant improvements in a number of clinically relevant cases, troublesome symptoms, such as Pyrexia, may still occur.
Cubicin Side Effect Report#9744524
Urosepsis
This Urosepsis problem was reported by a consumer or non-health professional from US. A 75-year-old female patient (weight: NA) was diagnosed with the following symptoms/conditions: enterococcal infection,staphylococcal infection,osteomyelitis,off label use. On NS this consumer started treatment with Cubicin (dosage: NA). The following drugs were being taken at the same time: NA. When using Cubicin, the patient experienced the following unwanted symptoms/side effects: UrosepsisAlthough all drugs are carefully tested before they are licensed for use, they carry side effect risks. Some side effects, such as Urosepsis, may become evident only after a product is in use by the general population.
Cubicin Side Effect Report#9739547
Urosepsis
This Urosepsis side effect was reported by a health professional from US. A 75-year-old female patient (weight:NA) experienced the following symptoms/conditions: enterococcal infection,staphylococcal infection,osteomyelitis,off label use.The patient was prescribed Cubicin (drug dosage: NA), which was initiated on NS. Concurrently used drugs: NA..After starting to take Cubicin the consumer reported adverse symptoms, such as: UrosepsisThese side effects may potentially be related to Cubicin.
Cubicin Side Effect Report#9736326
Pleuritic Pain, Pulmonary Artery Dilatation, Joint Range Of Motion Decreased, Joint Swelling, Computerised Tomogram Abnormal, Musculoskeletal Chest Pain, Skin Discolouration, Herpes Zoster, Staphylococcal Bacteraemia
This is a report of a 60-year-old male patient (weight: NA) from US, suffering from the following health symptoms/conditions: staphylococcal infection,rheumatoid arthritis, who was treated with Cubicin (dosage: NA, start time: 201206), combined with:
  • Enbrel
  • Vancomycin
  • Prednisone
  • Cellcept
  • Aspirin
  • Levothyroxine
  • Lisinopril
  • Metoprolol
and developed a serious reaction and side effect(s): Pleuritic Pain, Pulmonary Artery Dilatation, Joint Range Of Motion Decreased, Joint Swelling, Computerised Tomogram Abnormal, Musculoskeletal Chest Pain, Skin Discolouration, Herpes Zoster, Staphylococcal Bacteraemia after the beginning of treatment. This case can indicate the possible existence of increased vulnerability to Cubicin treatment in male patients, resulting in Pleuritic Pain side effect. The patient was hospitalized.
Cubicin Side Effect Report#9734419
Eosinophilic Pneumonia Acute, Dyspnoea, Hypoxia, Cough, Pyrexia
This report suggests a potential Cubicin Eosinophilic Pneumonia Acute side effect(s) that can have serious consequences. A 73-year-old male patient (weight: NA) from GB was diagnosed with the following symptoms/conditions: arthritis infective,off label use and used Cubicin (dosage: NA) starting
Jul 15, 2013. After starting Cubicin the patient began experiencing various side effects, including: Eosinophilic Pneumonia Acute, Dyspnoea, Hypoxia, Cough, PyrexiaAdditional drugs used concurrently: NA. Although Cubicin demonstrated significant improvements in a number of clinically relevant cases, troublesome symptoms, such as Eosinophilic Pneumonia Acute, may still occur.
Cubicin Side Effect Report#9693761
Arthralgia, C-reactive Protein Increased, Dyspnoea, Eosinophil Count Increased, Eosinophilic Pneumonia, Fatigue, Lung Infiltration
This Arthralgia problem was reported by a health professional from CA. A 60-year-old male patient (weight: NA) was diagnosed with the following symptoms/conditions: NA. On NS this consumer started treatment with Cubicin (dosage: 480 Mg, Qd). The following drugs were being taken at the same time:
  • Piperacillin, Tazobactam (3.375 Mg, Q6h)
  • Asa
  • Atorvastatin
  • Diazepam
  • Hydromorphone
  • Oxycodone
  • Salbutamol
  • Spiriva
When using Cubicin, the patient experienced the following unwanted symptoms/side effects: Arthralgia, C-reactive Protein Increased, Dyspnoea, Eosinophil Count Increased, Eosinophilic Pneumonia, Fatigue, Lung InfiltrationThe patient was hospitalized.Although all drugs are carefully tested before they are licensed for use, they carry side effect risks. Some side effects, such as Arthralgia, may become evident only after a product is in use by the general population.
Cubicin Side Effect Report#9688668
Cardiac Valve Vegetation, Embolism, Staphylococcal Bacteraemia, Endocarditis Staphylococcal, No Therapeutic Response
This Cardiac Valve Vegetation side effect was reported by a health professional from GB. A 40-year-old male patient (weight:NA) experienced the following symptoms/conditions: endocarditis staphylococcal,off label use.The patient was prescribed Cubicin (drug dosage: 6 Mg/kg, Unk), which was initiated on 201002. Concurrently used drugs: NA..After starting to take Cubicin the consumer reported adverse symptoms, such as: Cardiac Valve Vegetation, Embolism, Staphylococcal Bacteraemia, Endocarditis Staphylococcal, No Therapeutic ResponseThese side effects may potentially be related to Cubicin.
Cubicin Side Effect Report#9686699
Infection
This is a report of a 86-year-old male patient (weight: NA) from US, suffering from the following health symptoms/conditions: infection, who was treated with Cubicin (dosage: 6 Mg/kg, Qd, start time: 201301), combined with:
  • Levaquin (Unk Unk, Qd)
and developed a serious reaction and side effect(s): Infection after the beginning of treatment. This case can indicate the possible existence of increased vulnerability to Cubicin treatment in male patients, resulting in Infection side effect.
Cubicin Side Effect Report#9686255
Urinary Tract Infection
This report suggests a potential Cubicin Urinary Tract Infection side effect(s) that can have serious consequences. A 13-year-old male patient (weight: NA) from US was diagnosed with the following symptoms/conditions: device related infection,off label use and used Cubicin (dosage: 4 Mg/kg, Qd) starting NS. After starting Cubicin the patient began experiencing various side effects, including: Urinary Tract InfectionAdditional drugs used concurrently: NA. Although Cubicin demonstrated significant improvements in a number of clinically relevant cases, troublesome symptoms, such as Urinary Tract Infection, may still occur.
Cubicin Side Effect Report#9686254
Eosinophilic Pneumonia
This Eosinophilic Pneumonia problem was reported by a physician from US. A 75-year-old female patient (weight: NA) was diagnosed with the following symptoms/conditions: NA. On NS this consumer started treatment with Cubicin (dosage: Unk Unk Unk). The following drugs were being taken at the same time: NA. When using Cubicin, the patient experienced the following unwanted symptoms/side effects: Eosinophilic PneumoniaThe patient was hospitalized.Although all drugs are carefully tested before they are licensed for use, they carry side effect risks. Some side effects, such as Eosinophilic Pneumonia, may become evident only after a product is in use by the general population.
Cubicin Side Effect Report#9686240
Injection Site Erythema
This Injection Site Erythema side effect was reported by a consumer or non-health professional from US. A 18-year-old male patient (weight:NA) experienced the following symptoms/conditions: osteomyelitis.The patient was prescribed Cubicin (drug dosage: 500 Mg, Unk), which was initiated on NS. Concurrently used drugs: NA..After starting to take Cubicin the consumer reported adverse symptoms, such as: Injection Site ErythemaThese side effects may potentially be related to Cubicin.
Cubicin Side Effect Report#9684443
Blood Creatine Phosphokinase Increased, Full Blood Count Abnormal, Metabolic Function Test Abnormal
This is a report of a 23-year-old male patient (weight: NA) from US, suffering from the following health symptoms/conditions: staphylococcal infection,sepsis, who was treated with Cubicin (dosage: 500 Mg, Unk, start time:
Oct 26, 2012), combined with: NA. and developed a serious reaction and side effect(s): Blood Creatine Phosphokinase Increased, Full Blood Count Abnormal, Metabolic Function Test Abnormal after the beginning of treatment. This case can indicate the possible existence of increased vulnerability to Cubicin treatment in male patients, resulting in Blood Creatine Phosphokinase Increased side effect.
Cubicin Side Effect Report#9684388
Thrombocytopenia
This report suggests a potential Cubicin Thrombocytopenia side effect(s) that can have serious consequences. A 57-year-old patient (weight: NA) from US was diagnosed with the following symptoms/conditions: staphylococcal bacteraemia and used Cubicin (dosage: 6 Mg/kg, Q48h) starting NS. After starting Cubicin the patient began experiencing various side effects, including: ThrombocytopeniaAdditional drugs used concurrently:
  • Coumadin (Unk Unk, Unk)
  • Vitamin C (Unk Unk, Unk)
  • Prilosec (Unk Unk, Unk)
The patient was hospitalized. Although Cubicin demonstrated significant improvements in a number of clinically relevant cases, troublesome symptoms, such as Thrombocytopenia, may still occur.
Cubicin Side Effect Report#9684368
Neuropathy Peripheral
This Neuropathy Peripheral problem was reported by a consumer or non-health professional from US. A 50-year-old female patient (weight: NA) was diagnosed with the following symptoms/conditions: diabetic foot. On NS this consumer started treatment with Cubicin (dosage: 5.5 Mg/kg, Unk). The following drugs were being taken at the same time: NA. When using Cubicin, the patient experienced the following unwanted symptoms/side effects: Neuropathy PeripheralAlthough all drugs are carefully tested before they are licensed for use, they carry side effect risks. Some side effects, such as Neuropathy Peripheral, may become evident only after a product is in use by the general population.
Cubicin Side Effect Report#9684367
Neuropathy Peripheral
This Neuropathy Peripheral side effect was reported by a consumer or non-health professional from US. A 71-year-old male patient (weight:NA) experienced the following symptoms/conditions: NA.The patient was prescribed Cubicin (drug dosage: 570 Mg, Q24h), which was initiated on NS. Concurrently used drugs:
  • Rocephin (2 Gm, Q12h)
.After starting to take Cubicin the consumer reported adverse symptoms, such as: Neuropathy PeripheralThese side effects may potentially be related to Cubicin.
Cubicin Side Effect Report#9684362
Blood Potassium Increased
This is a report of a 61-year-old female patient (weight: NA) from US, suffering from the following health symptoms/conditions: NA, who was treated with Cubicin (dosage: 300 Mg, Qd, start time:
Nov 29, 2012), combined with: NA. and developed a serious reaction and side effect(s): Blood Potassium Increased after the beginning of treatment. This case can indicate the possible existence of increased vulnerability to Cubicin treatment in female patients, resulting in Blood Potassium Increased side effect.


1 of 69 


The appearance of Cubicin on this list does not mean that FDA has concluded that the drug has the listed risk. It means that FDA has identified a potential safety issue, but it does not mean that FDA has found a causal relationship between the drug and the listed risk.

Track Your Side Effects

Note Your Observations

It is really important to keep track of your health symptoms, right from the time you start a new medicine. You can do it any way you prefer: in a notebook, in a computer file or using our online tool. You should also note down any other medicines you are taking at the same time, because there could be an interaction between these medicines.

Why Your Notes are Important

Your notes could be helpful in several ways:

  • You can use them to remind you of details that may alert your health care professional(s) to a problem
  • You will have a record to refer to in the future, in case you are ever prescribed the same medicine again

  • Log Form

    You can use the following log form to write down important information, like the date and time you experienced a side effect and your symptoms, how strong the symptoms were, and any other medicines you were using.

    Medicine Name and Dosage:
    Side Effects Scale Date & Time Other Medicine(s) or Treatment(s)
    Scale: 1 = very mild to 10 = very bad

    Side effects reports are analyzed to discover potential health product safety signals. Some important reactions may take an extremely long time to develop or occur infrequently. Continued monitoring of adverse reactions is thus essential to maintain a comprehensive safety and effectiveness profile of health products.

    You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.

    Cubicin reports list potential signals of serious risks and new safety information that were identified using the FDA Adverse Event Reporting System (FAERS).
    FAERS is a database that contains information on adverse event and medication errors reports submitted to FDA by healthcare professionals (such as physicians, pharmacists, nurses and others), consumers (such as patients, family members, layers and others) and manufacturers.

    Discuss Cubicin Side Effects

    Did You Have a Cubicin Side Effect?

    Yes, Severe
    Yes, Moderate
    Yes, Minor
    No

    How Effective is Cubicin for You?

    Exceeded Expectations
    Effective
    Somewhat Effective
    Not Effective

    Cubicin Safety Alerts, Active Ingredients, Usage Information

    Cubicin Dosage, Warnings, Usage.

    Side Effects reported to FDA: 1702

    Cubicin safety alerts: 2013 2010 2008

    Reported deaths: 543

    Reported hospitalizations: 603

    Cubicin (daptomycin): Drug Safety Communication - Risk of Eosinophilic Pneumonia

    [Posted 07/29/2010]

    AUDIENCE: Infectious Disease, Pulmonology

    ISSUE:  FDA notified healthcare professionals and patients about the potential for developing eosinophilic pneumonia during treatment with Cubicin (daptomycin), an intravenous antibacterial drug indicated for use in treatment of serious skin infections and bloodstream infections. Eosinophilic pneumonia is a rare but serious condition where a type of white blood cell (eosinophil) fills the lungs. Symptoms of eosinophilic pneumonia include fever, cough, shortness of breath, and difficulty breathing. Eosinophilic pneumonia may lead to progressive respiratory failure and is potentially fatal if not quickly recognized and appropriately managed. 

    BACKGROUND: FDA has reviewed published case reports of Cubicin-associated eosinophilic pneumonia and conducted a review of post-marketing adverse event reports from the FDA's Adverse Event Reporting System. FDA's review identified 7 cases of eosinophilic pneumonia between 2004 and 2010 that were most likely associated with Cubicin. Based on these reviews, FDA determined that eosinophilic pneumonia can be associated with Cubicin use and requested that the manufacturer of Cubicin include this information in the Warnings and Precautions and Adverse Reactions, Post-Marketing Experience sections of the drug label.

    RECOMMENDATION: Healthcare professionals should closely monitor patients being treated with Cubicin for eosinophilic pneumonia. Patients receiving Cubicin should immediately contact their healthcare professional if they develop a new or worsening fever, cough, shortness of breath, or difficulty breathing.

    Additional information for Healthcare Professionals, Information for Patients, a Data Summary, and References are provided in the Drug Safety Communication at the link below.

    [07/29/2010 - Drug Safety Communication - FDA]
    [Jan 2010 - Cubicin (daptomycin) Prescribing Information - Cubist Pharmaceuticals]

    Latest Cubicin clinical trials